Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Michael James PhD
Assistant Professor
Department of Surgery
Division of Administration

OFFICE ADDRESS:
Translational and Biomedical Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226
Phone: 414-955-7572
Fax: 414-955-6059
Email: mjames@mcw.edu

EDUCATION:
1988 - 1992 Valedictorian, Stuart-Menlo High School, Stuart, IA
1992 - 1996 BS- cum laude - Microbiology, Iowa State University, Ames, IA
1997 - 1998 MT(ASCP),CLS(NCA), Mercy School of Clinical Laboratory Science, Des Moines, IA
2000 - 2006 PhD - Microbiology, University of Iowa, Carver College of Medicine, Iowa City, IA

RESEARCH ADMINISTRATIVE APPOINTMENTS:
1995 - 1997 Research Assistant, Veterinary Medicine Research Institute, Iowa State University, Ames, IA
1998 - 1999 Medical Technologist, DSM Pediatric and Adolescent Clinic, Des Moines, IA
1999 - 2000 Centers for Disease Control/APHL EID Fellow, University Hygienic Laboratory, University of Iowa, Iowa City, IA
2000 - 2006 Graduate Research Assistant, University of Iowa, Iowa City, IA
2006 - 2010 Postdoctoral Research Associate, Washington University School of Medicine, St. Louis, MO
2010 - 2014 Research Assistant Professor, Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI
2014 - Present Assistant Professor of Surgical Oncology, Surgery, Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
MT/CLS
06/1998
None
 
AWARDS AND HONORS:
1995 HHMI Research Assistantship in the Biological Sciences Award, Iowa State University, Ames, IA
1996 Graduation with Distinction (Cum Laude), Iowa State University, Ames, IA
1998 MSCLS Scholarship Award, Mercy School of Clinical Laboratory Science, Des Moines, IA
1999 CDC/APHL Emerging Infectious Diseases Fellowship Award, Centers for Disease Control and Prevention, Atlanta, GA
2003 Graduate Student Senate Travel Award , University of Iowa, Iowa City, IA
2014 T. Michael Bolger Standing Ovation Award Nominee, MCW Student Assembly
2015 NSF I-Corps Award, NSF I-Corps Milwaukee Site
2015 SE Wisconsin Healthcare Innovator of the Year, CTSI / Bridge to Cures
2016 Wisconsin Governor's Business Plan Contest, Finalist, Wisconsin Technology Council
2016 LES International Business Plan Contest, Members Choice and Best Student Team Awards, Licensing Executives Society

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
2010 - 2014 Medical College of Wisconsin Cancer Center & Cancer Susceptibility and Chemoprevention Program (Member)
2014 - Present MCW CC Tumor Progression and Metastasis Program (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorial Board
06/2013 - Present Journal of Pharmacology & Clinical Toxicology
Journal Review
2009 - Present Int. J. Cancer
2012 - Present Annals of Human Genetics
2013 - Present Molecular Carcinogenesis
2014 - Present Journal of Cancer Research and Clinical Oncology
2015 - Present BMC Cancer
2015 - Present World Journal of Gastroenterology
2015 - Present Tumor Biology
2016 - Present Experimental Lung Research
2016 - Present Scientific Reports
2016 - Present Oncotarget
2017 - Present Current Bioinformatics

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
The role of deubiquitinating enzyme USP33 in Slit-Robo signaling in lung cancer
Source:
NCI
Role:
Co-Investigator
PI:
Wu (Northwestern)
Dates:
02/01/2014 - 01/31/2019
Direct Funds:
$1,157,830
 
Source:
American Cancer Society
Role:
PI
Dates:
01/01/2016 - 12/31/2017
Direct Funds:
$29,964
 
Title:
Wellcome Trust Feasibility Award
Source:
Wellcome Trust
Role:
PI
Dates:
07/21/2016 - 10/03/2016
Direct Funds:
$26,400
 
Title:
Mechanisms of CRR9-Mediated Pancreatic Cancer Chemoresistance
Source:
WeCare Foundation
Role:
PI
Dates:
09/01/2016 - 08/31/2017
Direct Funds:
$50,000
 
Non-Peer Review
Title:
MCW Department of Surgery -Theodore W. Batterman Family Foundation
Role:
PI
Dates:
10/27/2014 - 06/30/2016
 
Title:
MCW Department of Surgery - Donald C. Ausman Family Foundation
Role:
PI
Dates:
10/27/2014 - 06/30/2016
 
Title:
NSF I-Corps Award
Source:
National Science Foundation
Role:
PI
Dates:
2016 - Present
Direct Funds:
$2,400
 
Source:
CTSI / Bridge to Cures
Role:
PI
Dates:
2016 - Present
Direct Funds:
$50,000
 
Pending
Peer Review
Title:
Investigation of a Novel Therapeutic Target and Mediator of Chemoresistance and Survival in Pancreatic Cancer
Source:
NCI
Role:
PI
Dates:
09/01/2017 - 08/31/2022
Direct Funds:
$1,655,500
 
Title:
Development of first-in-class therapeutic antibodies targeting CRR9 for resistant cancers
Source:
Harrington Discovery Institute, University Hospitals, Cleveland OH
Role:
PI
Dates:
01/01/2018 - 12/31/2019
Direct Funds:
$100,000
 
Prior
Peer Review
Title:
Functional Studies of Candidate Lung Cancer Susceptiblity Genes
Source:
NCI U19 - CA148127
Role:
Co-Investigator
PI:
Amos (Dartmouth)
Dates:
- 06/30/2014
 

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
Novel Tumor Survival Function of CLPTM1L; A Discovery in Lung Cancer Susceptibility Driven by GWAS., MCW Cancer Center Basic Sciences Retreat, Crowne Plaza Hotel, Wauwatosa, WI, 2012
Novel Germline Determinants of Lung Cancer Susceptibility: Discoveries Driven by Post GWAS Functional Studies, MCW Cancer Center Mol. Carcinogenesis and Chemoprevention Program, MCW, Milwaukee WI, 2012
Cancer Cell Biology Meeting, Medical College of Wisconsin, 2013
Therapeutic targeting of a novel cell-surface tumor survival protein, Milwaukee Quick Pitch- a First Look forum, University Club of Milwaukee, Milwaukee, WI, 2014
Michael James, Johnathan Ebben, SE Wisconsin Healthcare Innovation Pitch Event, Milwaukee, WI, 2015
ER Stress in Pancreatic Cancer, Pancreas Club, Medical College of Wisconsin, 2016
Therapeutic Targeting of Cisplatin Resistance Related Protein 9 (CRR9), Gynecologic Onocology Working Group Meeting, Medical College of Wisconsin, 2016
Poster, DNA Tumor Viruses Conference, Madison, WI, - 2004
Basic Science to Business: An Unexpected Journey into Entrepreneurship, Spotlight on Science, MCW Postdoctoral Industry Consultants, Medical College of Wisconsin, Milwaukee WI, - 2016
 
Regional
Essential Biotechnology LLC, Wisconsin Governor's Business Plan Competition, Wisconsin Entrepreneur's Conference, Madison, WI, - 2016
Poster, University of Iowa Department of Microbiology Retreat, - 2005
Speaker, HHMI Research Assistantship in the Biological Sciences Program, Ames, IA, - 1995
Speaker, APHL Conference, University of Iowa Hygienic Laboratory, - 2000
 
National
Evaluating the Functional Relevance of SNPs: Application to hTERT and CLPTM1L Genes in Lung Cancer, Institutional Grand Rounds, MD Anderson Cancer Center, Houston, TX, 2012
Michael A. James, Johnathan Ebben, Dustin Deming, Susan Tsai, CLPTM1L and GRP78 Interact and Promote Pancreatic Tumor Survival Under ER-Stress and Chemoresistance Through Cell-Surface Translocation and Interaction with PI3K, AACR Pancreatic Cancer Meeting, Orlando, FL, USA, 05/14/2016 - Present
Poster, Washington University Postdoctoral Symposium, - 2009
Speaker, Centers for Disease control and Prevention EID Fellowship Program, Atlanta, GA, - 2000
 
International
Poster, DNA Tumor Viruses Conference, Trieste, Italy, - 2003
 

MEDICAL COLLEGE TEACHING ACTIVITIES:
Medical Student Education
2014 Pharmacology, POPS Pharmacokinetics Teaching Conference
 
Resident and Fellow Education
09/01/2016 - Present Mentored Intern
 

EXTRAMURAL TEACHING:
Medical Student Education
2004 University of Iowa, Carver College of Medicine, Medical Microbiology Laboratory
 
Graduate Student Education
2003 University of Iowa, General Microbiology Laboratory
2005 University of Iowa, Iowa City, IA, Immunology
 

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Medical Students
Johnathan Ebben, Medical College of Wisconsin, 06/15/2011 - 07/15/2011 MSTP Student
 
Graduate Students
PhD
Yongik Lee, Medical College of Wisconsin, 09/01/2011 - 10/31/2011
Rachel Leiberman, Medical College of Wisconsin, 01/2012 - 03/2012
 

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
High School Students
Albert Shih, Washington University in St. Louis, 06/01/2009 - 08/31/2009 Mentored Intern
 

INTELLECTUAL PROPERTY:
03/12/2013 - Present MCW 1756 Patent Granted: TARGETING CLPTM1L BY RNA INTERFERENCE FOR TREATMENT AND PREVENTION OF CANCER, US 61.777.711

RESEARCH INTERESTS:
The goal of my research is to understand key tumor cell survival mechanisms and exploit them for better cancer therapy. Broadly, my expertise lies in molecular and cellular pathobiology. I have applied this expertise to the functional evaluation of novel cancer susceptibility candidates. The application of murine modeling, cell biology and molecular biology techniques has allowed me to elucidate roles for RGS17 in familial lung cancer through the cAMP/PKA/CREB signaling axis; for cis-regulated Xrn2 in proliferation and differentiation processes in human lung epithelial cells; and recently CLPTM1L/CRR9 as an anti-apoptotic factor that is necessary for Ras induced transformation and tumorigenesis. I have developed inhibitory monoclonal antibody technologies targeting CRR9 for cancer therapy and chemosensitization. My recent work has brought together these novel therapeutic targets and insight into the stress response in tumor cells. I have necessarily formed a collaborative team of highly experienced and eminent clinicians and scientists to drive both scientific interests and clinical development of anti-CRR9 therapeutics. I continue to utilize my experience in cell biology, molecular signaling, and mouse models of cancer to study the role of CRR9 in the ER stress response and pancreatic tumorigenesis and as a diagnostic and theranostic biomarker for cancer.


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. CLPTM1L/CRR9 Ectodomain Interaction with GRP78 at the Cell Surface Signals for Survival and Chemoresistance upon ER Stress in Pancreatic Adenocarcinoma Cells. Clarke WR, Amundadottir L,and James MA. Int. J. Can. Accepted 11/2018
2. Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer. 2018 03 27;18(1):335. PMCID: PMC5870823
3. Bodle CR, Mackie DI, Hayes MP, Schamp JH, Doorn JA, Houtman JCD, James MA, and Roman DL. Natural Products Discovered in a High Throughput Screen Identified as Inhibitors of RGS17, Cytostatic and Cytotoxic Agents for Lung, Prostate Cancers. J Nat Prod. 2017 Jun 16. doi: 10.1021/acs.jnatprod.7b00112.
4. Laszlo G Puskas, Imola Man, Gabor Szebeni, Laszlo Tiszlavicz, Susan Tsai, and Michael A. James. Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling. Mol Cancer Ther; May 15;985 2016
5. Lee Y, Wang Y, James MA, Jeong J, You M. Inhibition of IGF1R Signaling Abrogates the Resistance to Afatinib (BIBW2992) in EGFR T790M Lung Cancer Cells. Molecular Carcinogenesis, June 4, 2015
6. Lieberman R, Xiong D, James MA, Han Y, Amos C, et al. Functional characterization of RAD52 as a lung cancer susceptibility gene in the 12p13.33 locus. Molecular Carcinogenesis, May 27, 2015
7. James MA, William L. Seibel, Elena Kupert, Xiao X Hu, Vishwakanth Y. Potharla, Marshall W. Anderson. Novel, soluble compound, C25, sensitizes to TRAIL-induced apoptosis through upregulation of DR5 expression. Anti-Cancer Drugs, Jun 26(5):518-30, 2014.
8. James MA, Vikis HG, Tate E, Rymaszewski AL and You M. CRR9/CLPTM1L Regulates Cell Survival Signaling and is Required for Ras Transformation and Lung Tumorigenesis. Cancer Res. 74(4); 1–12, 2013
9. James MA, Wen W, Wang Y, Byers LA, Heymach JV, Coombes KR, Girard L, Minna J, You M. Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus. PLoS One 7(6):e36116, 2012
10. Liu P, Morrison C, Wang L, Xiong D, Vedell P, Cui P, Hua X, Ding F, Lu Y, James M, Ebben JD, Xu H, Adjei AA, Head K, Andrae JW, Tschannen MR, Jacob H, Pan J, Zhang Q, Van den Bergh F, Xiao H, Lo KC, Patel J, Richmond T, Watt MA, Albert T, Selzer R, Anderson M, Wang J, Wang Y, Starnes S, Yang P, M You. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis May 2, 2012
11. Ding F,James MA, You M. Exome Sequencing Reveals SYNE1 as a Candidate Susceptibility Gene for Familial Lung Cancer with Frequent Mutation. (Submitted)
12. Xiao H, Wang L, James MA, Yang P, You M, XRN2, a candidate lung cancer susceptibility gene, mediates let-7 degradation in human cells. 2012 (submitted)
13. Xiong D, Vedell P, Cui P, Ding F, James MA, Andrae JW, Pan J, Zhang Qi, Van den Bergh F, Janson M, Lu Y, Tschannen MR, Jacob H, Head K, Lo KC, Wang Y, You M. Frequent Alterations of Chromatin Remodeling and DNA Damage Pathways in Lung Cancer with Diverse Histologies, 2012(in review)
14. Lu Y, Liu P, Van den Bergh F, Zellmer V, James M, Wen W, Grubbs CJ, Lubet RA, You M. Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer. Cancer Prev Res 2012 Feb;5(2):248-59.
15. Freedman ML, Monteiro AN, Gayther SA, Coetzee GA, Risch A,Plass C, Casey G, De Biasi M, Carlson C, Duggan D, James MA, Liu P, Tichelaar JW, Vikis HG, You M & Mills IG. Principles for the post-GWAS functional characterization of cancer risk loci. Nature Genetics. 43(6):513-518 2011
16. Wang Y, James MA, Wen W, He J, Lu Y, Szabo E, Lubet R, and You M. Chemopreventive Effects of Pioglitazone on Chemically Induced Lung Carcinogenesis in Mice. Molecular Cancer Therapeutics. 9(11):3074-82 2010
17. James MA, Fu H, Liu Y, Chen D, and You M. Dietary Administration of Berberine Alone or in Phellodendron amurense Extract is Equally Effective in the Inhibition of Lung Tumorigenesis. Molecular Carcinogenesis Nov. 8 2010
18. Lu Y, Liu PY, James MA, Vikis H, Liu H, Wen W, Franklin A and You M. Genetic Variants Cis-regulating Xrn2 Expression Contribute to the Risk of Spontaneous Lung Cancer. Oncogene. 28(45) 2009
19. Bodle CR, Mackie DI, Hayes MP, Schamp JH, Doorn JA, Houtman JCD, James MA, and Roman DL. Natural Products Discovered in a High Throughput Screen Identified as Inhibitors of RGS17, Cytostatic and Cytotoxic Agents for Lung, Prostate Cancers. J Nat Prod. 2017 Jun 16. doi:10.1021/acs.jnatprod.7b00112.
20. Liu PY, Vikis H, James MA, Lu Y, Wang DL, Liu HB, Wen WD, Wang Y, You M. Haplotype and cell proliferation analyses of candidate lung cancer susceptibility genes on chromosome 15q24-25.1. Cancer Res. 69(19):7844-50 2009
21. Liu Y, Vikis H, James MA, Lu Y, Wang DL, Liu HB, Wen W, Wang Y, You M. Identification of Las2, a Major Modifier Gene Affecting the Pas1 Mouse Lung Tumor Susceptibility Locus. Cancer Res. 69(15):6290-8 2009
22. You M, Wang D, Liu P, Vikis H, James MA, Lu Y, Wang Y, et al. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. Clin. Can. Res. 15(8):2666-74 2009
23. James MA, Lu Y, Liu Y, Vikis HG, You M. RGS17, an Overexpressed Gene in Human Lung and Prostate Cancer, Induces Tumor Cell Proliferation Through the cAMP-PKA-CREB Pathway. Cancer Res. 69(5):2108-16 2009
24. Lu Y, Yi Y, Liu P, Wen W, James MA, Wang D, You M. Common human cancer genes discovered by integrated gene-expression analysis. PLoS ONE. 2007 Nov 7;2(11):e1149.
25. Vikis H, Sato M, James MA, Wang D, Wang Y, Wang M, Jia D, Liu Y, Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Yang P, Wiest JS, Fain PR, Schwartz AG, Gazdar A, Gaba C, Rothschild H, Mandal D, Kupert E, Seminara D, Viswanathan A, Govindan R, Minna J, Anderson MW, You M. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res. 2007 May 15;67(10):4665-70.
26. James MA, Lee JH, Klingelhutz AJ. HPV16-E6 associated hTERT promoter acetylation is E6AP dependent, increased in later passage cells and enhanced by loss of p300. Int J Cancer. 2006 Oct 15;119(8):1878-85.
27. James MA, Lee JH, Klingelhutz AJ. Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J Virol. 2006 Jun;80(11):5301-7.
28. Kramer TT, Reinke CR, James MA. Reduction of fecal shedding and egg contamination of Salmonella enteritidis by increasing the number of heterophil adaptations. Avian Dis. 1998 Jul-Sep;42(3):585-8.
29. Clarke WR, Amundadottir L, James MA. CLPTM1L/CRR9 ectodomain interaction with GRP78 at the cell surface signals for survival and chemoresistance upon ER stress in pancreatic adenocarcinoma cells. Int J Cancer. 2019 03 15;144(6):1367-1378.
 
Books, Chapters, and Reviews
1. Boyle K, James MA, Tsai S, Evans DB, Dwinell MB. Stromal Inflammation in Pancreatic Cancer: Mechanisms and Translational Applications. In: Neoptolemos JP, Urritia R, Abbruzzese J, Buchler MD. Pancreatic Cancer. 2nd Ed. Springer-Verlag New York. 2017. Doi: 10.1007/978-1-4939-6631-8_55-1
 
Editorials, Letters to Editor, Other
1. James MA. Rapid Test Kits for Influenza, University of Iowa University Hygienic Laboratory Hotline, 1999.
 
Abstracts
1. James MA, Ebben J, Deming D, Tsai S. CLPTM1L and GRP78 interact and promote pancreatic tumor survival under ER-stress and chemoresistance through cell-surface translocation and interaction with PI3K. Cancer Research 76(24 Supplement):B12, DOI: 10.1158/1538-7445.PANCA16-B12, 15 December 2016
 

jenkins-FCD Prod-353 9ccd8489072cb19f5b9f808bb23ed672c582f41e